Arbutus Biopharma Corporation (NASDAQ:ABUS) went up by 11.63% from its latest closing price compared to the recent 1-year high of $9.02. The company’s stock price has collected 18.68% of gains in the last five trading sessions. Press Release reported on 01/04/21 that Arbutus to Participate in Virtual Fireside Chat at H.C. Wainwright BioConnect 2021 Conference
Is It Worth Investing in Arbutus Biopharma Corporation (NASDAQ :ABUS) Right Now?
Plus, the 36-month beta value for ABUS is at 3.08. Opinions of the stock are interesting as 5 analysts out of 6 who provided ratings for Arbutus Biopharma Corporation declared the stock was a “buy,” while 0 rated the stock as “overweight,” 1 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $7.00. ABUS currently public float of 63.55M and currently shorts hold a 4.64% ratio of that float. Today, the average trading volume of ABUS was 3.14M shares.
ABUS’s Market Performance
ABUS stocks went up by 18.68% for the week, with a monthly jump of 26.69% and a quarterly performance of 35.00%, while its annual performance rate touched 42.57%. The volatility ratio for the week stands at 9.68% while the volatility levels for the past 30 days are set at 11.10% for Arbutus Biopharma Corporation. The simple moving average for the period of the last 20 days is 7.92% for ABUS stocks with a simple moving average of 58.26% for the last 200 days.
Analysts’ Opinion of ABUS
Many brokerage firms have already submitted their reports for ABUS stocks, with H.C. Wainwright repeating the rating for ABUS by listing it as a “Buy.” The predicted price for ABUS in the upcoming period, according to H.C. Wainwright is $10 based on the research report published on December 17th of the previous year 2020.
JMP Securities, on the other hand, stated in their research note that they expect to see ABUS reach a price target of $8, previously predicting the price at $10. The rating they have provided for ABUS stocks is “Mkt Outperform” according to the report published on July 27th, 2020.
ABUS Trading at 17.05% from the 50-Day Moving Average
After a stumble in the market that brought ABUS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -52.11% of loss for the given period.
Volatility was left at 11.10%, however, over the last 30 days, the volatility rate increased by 9.68%, as shares surge +17.71% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +48.45% upper at present.
During the last 5 trading sessions, ABUS rose by +18.68%, which changed the moving average for the period of 200-days by +91.15% in comparison to the 20-day moving average, which settled at $4.04. In addition, Arbutus Biopharma Corporation saw 21.69% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at ABUS starting from McElhaugh Michael J., who sale 40,000 shares at the price of $5.00 back on Dec 14. After this action, McElhaugh Michael J. now owns 1,327,457 shares of Arbutus Biopharma Corporation, valued at $200,032 using the latest closing price.
McElhaugh Michael J., the Chief Business Officer of Arbutus Biopharma Corporation, sale 20,000 shares at $5.01 during a trade that took place back on Jul 23, which means that McElhaugh Michael J. is holding 1,367,457 shares at $100,200 based on the most recent closing price.
Stock Fundamentals for ABUS
Current profitability levels for the company are sitting at:
- -1186.91 for the present operating margin
The net margin for Arbutus Biopharma Corporation stands at -2557.36. The total capital return value is set at -48.32, while invested capital returns managed to touch -104.22. Equity return is now at value 128.90, with -76.20 for asset returns.
Based on Arbutus Biopharma Corporation (ABUS), the company’s capital structure generated 30.72 points at debt to equity in total, while total debt to capital is 23.50.
When we switch over and look at the enterprise to sales, we see a ratio of 37.85, with the company’s debt to enterprise value settled at 0.10. The receivables turnover for the company is 3.98 and the total asset turnover is 0.04. The liquidity ratio also appears to be rather interesting for investors as it stands at 11.99.